- Home
- CBT vs PTGX Comparison
CBT vs PTGX Comparison
Compare CBT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBT
- PTGX
- Stock Information
- Founded
- CBT 2019
- PTGX 2006
- Country
- CBT United States
- PTGX United States
- Employees
- CBT N/A
- PTGX N/A
- Industry
- CBT Major Chemicals
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CBT Industrials
- PTGX Health Care
- Exchange
- CBT Nasdaq
- PTGX Nasdaq
- Market Cap
- CBT 4.0B
- PTGX 5.0B
- IPO Year
- CBT N/A
- PTGX 2016
- Fundamental
- Price
- CBT $61.37
- PTGX $85.30
- Analyst Decision
- CBT Hold
- PTGX Strong Buy
- Analyst Count
- CBT 3
- PTGX 9
- Target Price
- CBT $79.33
- PTGX $86.44
- AVG Volume (30 Days)
- CBT 477.0K
- PTGX 912.3K
- Earning Date
- CBT 11-03-2025
- PTGX 11-06-2025
- Dividend Yield
- CBT 2.92%
- PTGX N/A
- EPS Growth
- CBT N/A
- PTGX N/A
- EPS
- CBT 6.02
- PTGX 0.72
- Revenue
- CBT $3,713,000,000.00
- PTGX $209,217,000.00
- Revenue This Year
- CBT $6.09
- PTGX N/A
- Revenue Next Year
- CBT $3.05
- PTGX $140.23
- P/E Ratio
- CBT $10.22
- PTGX $117.38
- Revenue Growth
- CBT N/A
- PTGX N/A
- 52 Week Low
- CBT $58.99
- PTGX $33.31
- 52 Week High
- CBT $115.16
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- CBT 29.02
- PTGX 66.16
- Support Level
- CBT $60.03
- PTGX $76.70
- Resistance Level
- CBT $62.57
- PTGX $86.90
- Average True Range (ATR)
- CBT 1.94
- PTGX 3.20
- MACD
- CBT -0.10
- PTGX 0.30
- Stochastic Oscillator
- CBT 19.90
- PTGX 83.71
About CBT Cabot Corporation
Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into the following operating segments based on the product type; the Reinforcement Materials segment which generates maximum revenue provides reinforcing carbon products used in tires, and industrial products such as hoses, belts, extruded profiles, and molded goods; and the Performance Chemicals segment aggregates the specialty carbons, specialty compounds, fumed metal oxides, battery materials, inkjet colorants, and aerogel product lines. Geographically, the company derives maximum revenue from its customers in Europe, the Middle East, and Africa and the rest from the Americas and Asia Pacific region.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.